A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)

PHASE3CompletedINTERVENTIONAL

Enrollment

422

Participants

Timeline

Start Date

March 25, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

October 18, 2016

Conditions

Atopic Dermatitis

Interventions

DRUG

Dupilumab

Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered.

DRUG

Placebo

Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW).